| Name | EIDD-2749 |
| Description | EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses. |
| In vitro | EIDD-2749 (20 uM) is effective in synthesizing metabolism in HAE cells and is effective on human airway epithelial organoids[1]. |
| In vivo | In Balb/cJ mice (RSV infection model), EIDD-2749 (0.2, 1, 5 mg/kg; oral administration; once daily for 4 days) resulted in a statistically significant reduction in lung virus load[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 15 mg/mL (57.21 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.63 mM), Sonication is recommended. H2O : 50 mg/mL (190.7 mM), Sonication is recommended.
|
| Keywords | SARS-CoV-2 | SARSCoV | EIDD-2749 | EIDD2749 | EIDD 2749 | Antiviral | 4'-FlU ; 4'-Fluorouridine |
| Inhibitors Related | Dibenzofuran | Esculin | Methyl 2-amino-5-bromobenzoate | Hexane-2,5-dione | Deferiprone | Ribavirin | Hydroxychloroquine | Chloroquine phosphate | Sodium formate | α-Cyclodextrin | Artemisinin | Perflubron |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Multi-Target Compound Library | Anti-Viral Compound Library | Inhibitor Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Infection Compound Library | Nucleotide Compound Library |